Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
1.145
-0.025 (-2.14%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Can-Fite BioPharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-7.88-7.63-10.17-12.62-14.44
Upgrade
Depreciation & Amortization
0.010.020.010.010.01
Upgrade
Loss (Gain) From Sale of Investments
0.01-0.010.23-0.16-0.01
Upgrade
Stock-Based Compensation
0.360.260.260.470.36
Upgrade
Other Operating Activities
0.13-0.130.170.010.03
Upgrade
Change in Accounts Payable
0.19-0.47-0.060.39-1.6
Upgrade
Change in Unearned Revenue
-0.35-0.74-0.811.4-0.4
Upgrade
Change in Other Net Operating Assets
-0.110.27-0.430.643.99
Upgrade
Operating Cash Flow
-7.64-8.44-10.8-9.86-12.06
Upgrade
Capital Expenditures
-0.01-0-0.01-0.01-0.03
Upgrade
Investment in Securities
1.50.59.51-14.5-
Upgrade
Investing Cash Flow
1.50.59.5-14.51-0.03
Upgrade
Issuance of Common Stock
7.229.53-21.7617.68
Upgrade
Other Financing Activities
-0.51-0.39--1.31-
Upgrade
Financing Cash Flow
6.719.14-20.4617.68
Upgrade
Foreign Exchange Rate Adjustments
-0.020.1-0.110.03-0.02
Upgrade
Net Cash Flow
0.551.3-1.41-3.885.57
Upgrade
Free Cash Flow
-7.64-8.44-10.81-9.87-12.09
Upgrade
Free Cash Flow Margin
-1133.83%-1136.20%-1334.57%-1156.98%-1584.40%
Upgrade
Free Cash Flow Per Share
-0.00-0.01-0.01-0.02-0.03
Upgrade
Cash Interest Paid
---0.020.02
Upgrade
Levered Free Cash Flow
-4.82-5.12-6.51-5.98-7.41
Upgrade
Unlevered Free Cash Flow
-4.82-5.12-6.51-5.98-7.18
Upgrade
Change in Net Working Capital
0.10.280.46-1.58-1.32
Upgrade
Updated Aug 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q